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32S Abstracts June Supplement 2014mortality (adjusted hazard ratio [HR], 1.03; P < .001).
Compared with patients with IHC (N ¼ 419,009), overall
risk-adjusted mortality was lowest in patients with AVF (N
¼ 71,328; HR, 0.65; P < .001), followed by AVG (N ¼
17,544; HR, 0.83; P < .001). AVF was superior to IHC
and AVG for all age groups (P < .001; Fig 1). However,
there was a signiﬁcant change in the relative efﬁcacy of
AVG at age 45 based on spline modeling: there were no
differences comparing AVG to IHC for patients aged 18
to 44 years (adjusted HR, 0.90; P ¼ .12), but AVG was su-
perior to IHC for patients aged $45 years (adjusted HR,
0.82; P < .001).
Conclusions: Contrary to previous reports, our data
suggest that AVF is superior to AVG and IHC regardless
of patient age, including in octogenarians. In contrast,
the mortality beneﬁt of AVG over IHC may not apply to
younger age groups. All patients aged <45 years should
receive AVF for dialysis access whenever possible.
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Objectives: Dialysis access-associated steal syndrome
(DASS) complicates arteriovenous (AV) access surgery.
We describe our 10-year experience with DASS.
Methods: DASS operations were retrospectively
reviewed from July 2003 to July 2013. Demographics, symp-
toms, surgical details, and outcomes were collected. IRB
approvalwas secured, and aP< .05was considered signiﬁcant.
Results: A total of 201 patients had 218 episodes of
DASS. Mean age was 65 years, 62% were female. DASS
was caused by 175 AV ﬁstulas (80%), 41 prosthetic grafts
(19%) and two thigh grafts (1%); 87% were brachial artery
based. Twenty-two percent were referred for DASS from
other practices. All patients had grade 2 (48%) or 3 (52%)
DASS. Ninety-two percent (185) were available for follow-
up, with amedian follow-up of 23 days. There were no differ-
ences in preoperative comorbidities. Surgical managements,Table. Dialysis access-associated steal syndrome (DASS) surgi
Procedure No.
Grade
3 steal (%)
Time to
intervention
Ligation 73 67 39a
Distal revascularization & interval ligation
(DRIL)
59 64 210
Revision using distal inﬂow (RUDI) 21 19a 72
Banding 38 32a 24a
Proximalization of arterial inﬂow (PAI) 12 33 92
Radial artery ligation (RAL) 13 39 199
Total 216 52 72
aP < 0.05 vs DRIL.omitting thigh grafts due to low numbers, were compared
(Table). The 30-day complications included continued steal,
thrombosis, bleeding, infectious, or mortality. During the
study period, access volume increased from 1312 access cre-
ations for 2003-2008 to 1975 for 2008-2013. Percentage of
ﬁstulas (79% vs 86%), incidence of steal (4% vs 6%), and per-
centage of distal revascularization-interval ligation (DRIL)
procedures (25% vs 28%) was consistent across study periods.
Conclusions: DRIL and ligation were performed in
the most severe patients. Compared with ligation, DRIL
has equal symptom resolution, no increase in complica-
tions, and ﬁstula preservation. Compared with banding,
DRIL resulted in superior ﬁstula preservation and fewer
complications. DRIL should be considered the gold stan-
dard management for DASS.
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Background: Current synthetic grafts have high rates
of failure, due primarily to thrombosis and intimal hyper-
plasia. We have developed a tissue-engineered vascular
graft that consists of human extracellular matrix and is
similar in strength to native human vein and artery. This
investigational graft is currently in clinical studies for eval-
uation of safety and efﬁcacy in hemodialysis vascular access
in patients with end-stage renal disease. In this presenta-
tion, we describe the development, preclinical experience,
and early human implant experience for these tissue-engi-
neered vascular grafts.
Technical description: A video is presented on the
ﬁrst case in the United States in which a human tissue-engi-
neered vascular graft was implanted into a patient for he-
modialysis access. Perspective is presented on the key
developmental milestones that led to the ﬁrst clinical im-
plantation. These milestones include graft growth, animalcal outcomes
(days)
Native
AVF (%)
Fistula
preserved (%)
Improvement
of steal symptoms (%)
30-day
complications (%)
64a 0a 93 10
97 100 98 14
100 95 89 37
71a 89 75a 49a
83 100 100 44
100 100 100 0
80 64 90 22
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Volume 59, Number 6S Abstracts 33Sstudies, and clinical implantation of the graft. Banked hu-
man aortic smooth muscle cells were cultured in bioreac-
tors in vitro to produce vascular tissue grafts, and a
decellularization process was subsequently used to remove
immunogenic cellular antigens. Arteriovenous grafts were
implanted into nonhuman primates for up to 6 months
and were evaluated for patency, durability, cannulation,
rejection, and cellular repopulation. In addition, these
grafts were evaluated for long-term arterial reconstruction
in a canine model, using canine-derived grafts. In animal
studies, histologic analysis demonstrated evidence of host
vascular cell migration into grafts and endothelialization.
Little intimal hyperplasia was observed in animal studies.
These preclinical studies supported initiation of clinical
trials.
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Objectives: Optimal initial treatment for patients with
acute limb ischemia (ALI) remains undeﬁned. Although
clinical outcome data are inconsistent, catheter-directed
thrombolysis (CDT) with tissue plasminogen activator is
increasingly used. Patient-level analysis combining clinical
and economic data in a real-life setting is lacking. This
study compares clinical outcomes and cost effectivenessTable. Clinical and economic outcomes
Variable CDT (n ¼ 68) CDT + A (n ¼ 16) Open
AFS (%/N) 94/64 87/14
Readmissions (%/N) 16/11 31/5
Mortality (%/N) 0 6/1
Major bleed (%/N) 3/2 0
Reinterventions (%/N) 62/42 33/5
Initial hosp costs, $
Mean 31,804 27,779
SE 2436 5035
Readmission cost ($)
Mean 20,441 26,844
SE 4684 7306
Total cost
Mean 34,840 37,002
SE 2725 5628of initial treatment strategies for non-embolic ALI using
real-life patient-level data.
Methods: Medical records and hospital cost data were
analyzed for non-embolic ALI patients treated in four hos-
pitals over 3 years. A cost-effectiveness analysis was per-
formed using a decision tree analytical model. All costs
were valued based on cost-to-charge ratios.
Results: In 205 patients, initial treatments were CDT
alone (68) or with angioplasty (16), open surgery (60),
endovascular (33), and hybrid (28). Clinical and economic
outcomes are summarized in the Table. Although clinical
outcomes did not differ signiﬁcantly between groups, rein-
tervention rates during hospital stay, readmission rates, and
costs were highest in the CDT group. More than one re-
intervention was needed in 16% of patients in the CDT
group.
Conclusions: In this real-life study, initial treatment
of non-embolic limb ALI with currently available CDT
options was associated with greater healthcare resource
consumption and cost compared to other initial treatment
options.
Author Disclosures: A. J. Comerota: Nothing to
disclose; F. Lurie: Nothing to disclose; V. Vaidya:
Nothing to disclose.
SS24
Lessons Learned in the Surgical Treatment of
Neurogenic Thoracic Outlet Syndrome over 10 years
Kendall Likes, Megan S. Orlando, Serene Mirza, Quinn
Salditch, Anne Cohen, Ying W. Lum, Thomas Reifsnyder,
Julie Freischlag. Johns Hopkins Medical Institutions,
Baltimore, Md
Objectives: To evaluate our extensive experience in
the treatment of patients with neurogenic thoracic outlet
syndrome (NTOS) who underwent ﬁrst rib resection and
scalenectomy (FRRS) over a decade.
Methods: Patients treated with FRRS for NTOS from
2003 to 2013 were retrospectively reviewed using a pro-
spectively maintained database.
Results: Over the 10 years, 286 patients underwent
308 FRRS. During the ﬁrst 5-year period, 127 FRRS
were performed (96 female, 31 male), with an average
age of 36.9 years. During the second 5-year period, 181
FRRS were performed (143 female, 38 male), with an
average age of 33 years. Twenty-four children (age #18
years) underwent FRRS; nine during the ﬁrst 5 years andSurg (n ¼ 60) Endovasc (n ¼ 33) Hybrid (n ¼ 28) P
95/57 100/33 100/28 NS
7/4 6/2 3/1 <.05
1/1 0 0 NS
1/1 0 0 NS
7/4 12/4 18/5 <.00001
.01
16,636 20,751 21,134
2595 3494 3850
.05
7434 24,409 4156
9847 11,235 18,117
.0001
17,758 21,916 21,220
2921 3911 4309
